Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M497Revenue (TTM) $M26.1Net Margin (%)-590.5Altman Z-Score-4.5
Enterprise Value $M591EPS (TTM) $-1.5Operating Margin %-395.8Piotroski F-Score4
P/E(ttm)--Beneish M-Score0.1Pre-tax Margin (%)-590.2Higher ROA y-yY
Price/Book8.310-y EBITDA Growth Rate %--Quick Ratio7.0Cash flow > EarningsY
Price/Sales18.85-y EBITDA Growth Rate %29.5Current Ratio8.7Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-74.7Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-166.0Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M106ROIC % (ttm)-341.0Gross Margin Increase y-yN

Gurus Latest Trades with KERX

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
KERXJoel Greenblatt 2016-06-30 Add0.01%$4.54 - $6.76
($5.58)
$ 4.69-16%Add 206.30%77,976
KERXJoel Greenblatt 2016-03-31 Buy $3.17 - $5.38
($3.99)
$ 4.6918%New holding25,457
KERXSeth Klarman 2015-06-30 Add0.57%$9.32 - $12.73
($10.75)
$ 4.69-56%Add 15.24%25,791,678
KERXSeth Klarman 2015-03-31 Add0.88%$10.87 - $14.68
($12.86)
$ 4.69-64%Add 22.30%22,380,200
KERXSeth Klarman 2014-09-30 Add1.87%$12.71 - $18.19
($15.32)
$ 4.69-69%Add 73.62%18,300,000
KERXSeth Klarman 2014-06-30 Add1.04%$12.11 - $17.03
($14.16)
$ 4.69-67%Add 67.01%10,539,986
KERXSeth Klarman 2014-03-31 Buy 2.6%$12.16 - $16.88
($14.98)
$ 4.69-69%New holding6,310,850
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

KERX is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


KERX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Madison GregPresident and CEO 2016-08-09Sell1,622$4.224.74view
Madison GregPresident and CEO 2016-08-09Sell1,622$4.224.74view
Holmes Scott ACFO 2016-07-29Sell4,935$7.36-39.95view
Neylan John F.Chief Medical Officer 2016-07-25Sell1,217$7.43-40.51view
Adams BrianVP and General Counsel 2016-07-15Sell1,083$7.01-36.95view
Adams BrianVP and General Counsel 2016-07-05Sell660$6.66-33.63view
Madison GregPresident and CEO 2016-07-05Sell936$6.66-33.63view
Madison GregPresident and CEO 2016-05-09Sell1,873$5.42-18.45view
Neylan John F.Chief Medical Officer 2016-04-25Sell4,766$5.21-15.16view
Adams BrianVP and General Counsel 2016-04-15Sell1,060$5.05-12.48view

Quarterly/Annual Reports about KERX:

News about KERX:

Articles On GuruFocus.com
Seth Klarman Buys 25 Million Shares of Cascadian Therapeutics as Price Declines Jul 12 2016 
Klarman Gives Insight on Keryx Biopharmaceuticals Investment Jan 26 2016 
Seth Klarman Blames Market, Investments for Rare Down Year Jan 25 2016 
David Abrams Buys Stake in Heavy Equipment Company Dec 15 2015 
Why Seth Klarman Keeps Buying Keryx Biopharma Nov 03 2015 
Seth Klarman Raises Position in Keryx Biopharmaceuticals Oct 21 2015 
Seth Klarman Buys Pharmaceutical Company's Shares to Fund Drug Launch Oct 12 2015 
Is Seth Klarman right about Keryx Inc.? Jun 25 2015 
Seth Klarman Buys Pioneer Natural Resources, SunEdison Semiconductor Ltd, Atara Biotherapeutics Inc, May 15 2015 
Analysts Positive on Keryx Biopharmaceuticals, Inc. Despite Weak Prescription Data May 05 2015 

More From Other Websites
SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Keryx... Aug 22 2016
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Keryx Biopharmaceuticals, Inc. of a... Aug 22 2016
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Keryx... Aug 19 2016
SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Keryx... Aug 19 2016
Robbins Arroyo LLP: Keryx Biopharmaceuticals, Inc. (KERX) Misled Shareholders According to a... Aug 19 2016
ETF’s with exposure to Keryx Biopharmaceuticals, Inc. : August 18, 2016 Aug 18 2016
IMPORTANT INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Keryx... Aug 18 2016
5 Breakout Stocks Under $10 Set to Soar Aug 18 2016
Hagens Berman Reminds Investors in Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) of October 3, 2016... Aug 18 2016
INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Keryx... Aug 17 2016
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Keryx Biopharmaceuticals, Inc. of... Aug 17 2016
KERYX BIOPHARMACEUTICALS INC Financials Aug 16 2016
INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Keryx... Aug 16 2016
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against... Aug 16 2016
SHAREHOLDER NOTICE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Keryx... Aug 15 2016
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against... Aug 14 2016
SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Keryx... Aug 12 2016
KERYX SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS... Aug 12 2016
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Keryx... Aug 12 2016
INVESTOR NOTICE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Keryx... Aug 12 2016
SHAREHOLDER ALERT: Rosen Law Firm Reminds Keryx Biopharmaceuticals Inc. Investors of Important... Aug 12 2016
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Keryx Biopharmaceuticals, Inc. of... Aug 12 2016
Keryx Biopharmaceuticals Announces Interruption in Supply of Auryxia® (ferric citrate) and Second... Aug 01 2016
Keryx Biopharma reports 2Q loss Aug 01 2016
Keryx Biopharmaceuticals to Host Conference Call of Second Quarter 2016 Financial Results on Monday,... Jul 29 2016
Douglas Jermasek to Join Keryx Biopharmaceuticals as Vice President, Marketing and Strategy Jun 27 2016
Keryx Biopharmaceuticals Appoints Two New Board Members Jun 21 2016
Keryx Biopharmaceuticals to Present at JMP’s Life Science Conference on Tuesday, June 21 Jun 14 2016
Keryx Biopharma reports 1Q loss Apr 28 2016
Keryx Biopharmaceuticals Announces First Quarter 2016 Financial Results Apr 28 2016
Keryx Biopharmaceuticals to Host Conference Call of First Quarter 2016 Financial Results on... Apr 14 2016
Keryx Biopharmaceuticals Announces New Appointments and Changes to its Board of Directors Apr 01 2016
Keryx Biopharma reports 4Q loss Feb 25 2016
Keryx Biopharmaceuticals to Present at the 34th Annual J.P. Morgan Healthcare Conference on Monday,... Dec 22 2015
Keryx Announces Appointment of John P. Butler to its Board of Directors Dec 10 2015
Keryx Biopharmaceuticals Announces Participation at Two Upcoming Investor Conferences Nov 03 2015
Keryx Biopharma reports 3Q loss Oct 29 2015
Keryx Biopharmaceuticals Announces Third Quarter 2015 Financial Results Oct 29 2015
Keryx Biopharmaceuticals Announces $125 Million Private Placement of Convertible Senior Notes With... Oct 15 2015
Keryx Receives European Approval for Fexeric(R) (ferric citrate coordination complex) for the... Sep 24 2015
Keryx Biopharmaceuticals Announces Participation at Upcoming Investor Conferences Sep 09 2015
Keryx Biopharma reports 2Q loss Aug 05 2015
Keryx Biopharma reports 1Q loss May 04 2015
Keryx Biopharma reports 4Q loss Feb 27 2015
Keryx Biopharma misses Street 3Q forecasts Nov 06 2014
Correction: Keryx-Drug Approval story Sep 06 2014

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)